Data are owned by the German statutory health insurance SVLFG. To request the data please contact the institutional body of the SVLFG directly (<gleichgewicht@svlfg.de>). In order to fulfill the legal requirements to obtain that kind of data, researchers must conclude a contract with the SVLFG regarding data access. The licensee is permitted to use the data for the purpose of the research proposal only. Licensees are not allowed to pass the data to a third party, or to create Software or data bases with the exception of scientific publications. Moreover, the study has to be approved by the data protection officer both at the SVLFG and the research institute.

Introduction {#sec005}
============

Hip fractures are among the most frequently occurring fragility fractures in older adults, associated with a loss of quality of life, high mortality, and high use of healthcare resources \[[@pone.0232969.ref001]\]. Some of the highest hip fracture rates are seen in Europe and particularly in northern Europe--i.e., Denmark, Sweden and Norway \[[@pone.0232969.ref002], [@pone.0232969.ref003]\]. In 2010, the number of incident hip fractures in the EU has been estimated to amount to 610,000. Total costs of osteoporosis added up to about €37.4 billion. Hip fractures were determined to account for the majority (54%) of total osteoporosis costs \[[@pone.0232969.ref003]\].

In view of the growing population of older people, early and correct detection of those with an increased fracture risk is important to provide adequate treatment and reduce the socio-economic impact of fractures. Approaches to fracture risk assessment such as FRAX \[[@pone.0232969.ref004]\], Qfracture \[[@pone.0232969.ref005], [@pone.0232969.ref006]\] or the German DVO Tool \[[@pone.0232969.ref007]\] are well-established to predict osteoporotic fracture risk based on various (clinical) risk factors including e.g., increasing age, female gender, low body mass index, low bone mineral density (BMD), history of fragility fractures, history of falls, smoking, alcohol intake, glucocorticoid use, other causes of secondary osteoporosis \[[@pone.0232969.ref008]\]. Yet, these tools rely on direct patient information to receive parameters relevant for risk prediction. In addition, these risk assessment tools often assume linear relationships between risk factors and fracture outcome. Administrative claims data have become an important source of information for payers and policymakers to support health care decision making \[[@pone.0232969.ref009]\]. Moreover, claims data in Germany include information, which can be difficult to obtain when questionairs or interviews are used, because--as opposed to questionairs and interviews--the data is not prone to recall (e.g., patients who do not remember their prescription dates) or recruitment biases (i.e., the full cohort of insuree's and not just those who choose to participate are assessed). Therefore, we applied a Cox proportional hazards regression in a previous analysis to assess claims data's potential to predict fracture risk \[[@pone.0232969.ref010]\]. However, given the number and complexity of (longitudinal) individual-level information embedded in claims data, these traditional prediction modelling techniques may be less suited to capture higher-order interaction or nonlinear effects \[[@pone.0232969.ref011]\]. Only recently, advanced machine learning methods--e.g., neural networks, ensembling strategies or gradient boosting--have begun to be used for clinical prediction models \[[@pone.0232969.ref012], [@pone.0232969.ref013]\]. These new techniques may have the potential to enhance risk prediction, thereby improving the chances of correctly identifying high-risk populations and offering interventions in a more efficient and targeted way.

To date, it is difficult to estimate the potential of these techniques, because they are rarely systematically compared to traditional approaches. Furthermore, the utility largely depends on where and how they are employed. Miotto, Li \[[@pone.0232969.ref014]\] recently showed that unsupervised feature learning based on neural networks can significantly boost the consecutive disease classification from an area under the receiver operating curve (AUC) of 0.632 (worst alternative) to 0.773. However, other studies report rather small improvements in the AUC of around 3% when comparing modern machine learning techniques to traditional approaches \[[@pone.0232969.ref015], [@pone.0232969.ref016]\]. Thus, we believe that it is important to examine whether applying more complex algorithms as opposed to traditional regression techniques offers incremental value in various contexts to learn when this additional effort amounts to meaningful improvements.

It is often not straightforward to choose a priori the "best" prediction algorithm, but super learning \[[@pone.0232969.ref017], [@pone.0232969.ref018]\], an ensemble machine learning method, can assist researchers in making this decision by combining several (pre-identified) prediction algorithms into a single algorithm.

The aim of the study was to develop and validate a prediction algorithm for osteoporotic hip fracture based on claims data employing a superlearner approach.

Methods {#sec006}
=======

Ethics {#sec007}
------

The present study is a retrospective, observational, non-interventional study and all data were fully anonymized, therefore approval by an Ethics Committee was not required.

Sample {#sec008}
------

In this study, we used administrative claims data from April 2008 through March 2014 on 288,086 individuals aged 65 years and older, without level of care. This datasource was also used in a previous study of ours \[[@pone.0232969.ref010]\]. In Germany, there were three distinct levels of care until 2016, which were clearly defined and routinely assessed by a qualified physician or nurse. The classification depended on daily time needed for care (care level 1, 2, and 3 requiring basic care such as washing, feeding, or dressing for at least 0.75, 2, and 4 hours daily time, respectively) and on whether domestic supply was necessary \[[@pone.0232969.ref019]\]. Individuals with care level will already have an elevated risk of falls and fracture due to a higher level of functional disability and were therefore excluded. Notably, the dataset is limited to people working in agriculture and their families, because the data provider is the German agricultural sickness fund--in german: Sozialversichung für Landwirtschaft, Forsten und Gartenbau (SVLFG). We only included individuals, who were insured by the SVLFG on April 1, 2010 (baseline) with continuous insurance coverage for the 24 months pre-period--i.e., we excluded patients who switched to the SVLFG during the pre-period or after April, 1, 2010.

Outcome variable {#sec009}
----------------

The outcome variable was the first hip fracture--both osteoporotic and non-osteoporotic--occurring within 4 years after the index date--i.e., between April 1 2010 and 31 March 2014. Hospital admission and discharge diagnoses were used to identify hip fractures (International Classification of Diseases, 10^th^ revision, German Modification, ICD-10 codes: S72.0 to S72.2).

Predictor variables {#sec010}
-------------------

Numerous risk factors have been identified by prior research to predict hip fracture. We used information available within administrative claims data to determine potential risk factors. Age, gender, prior fracture history, and medication use were considered as candidate predictor variables.

Age was assessed at baseline. We further assessed whether at least one prior fracture within 2 years preceding baseline was recorded (yes/no). We distinguished between prior hip fracture (ICD-10 codes: S72.0 to S72.2), prior major osteoporotic fracture (i.e., hip, vertebra, forearm or humerus fractures) \[[@pone.0232969.ref020]\] and prior osteoporotic fracture (vertebra, pelvic, rib, humerus, forearm, tibia and fibula, clavicle, scapula, sternum, proximal femoral and other femoral fractures) \[[@pone.0232969.ref021]\]. Regarding medication use, we considered exposure (yes/no) to the following risk factors: (1) drugs for which an association with fracture risk has been well established, e.g., glucocorticoids, aromatase inhibitors, antidepressants, proton pump inhibitors \[[@pone.0232969.ref004], [@pone.0232969.ref006], [@pone.0232969.ref007]\], (2) drugs commonly prescribed for conditions that have been associated with increased fracture risk, e.g., antidiabetics, and (3) drugs prescribed for prevention and treatment of osteoporosis such as bisphosphonates, calcium, vitamin D and their combinations. Exposure was defined as at least two prescriptions recorded in the seven months before baseline \[[@pone.0232969.ref006], [@pone.0232969.ref022], [@pone.0232969.ref023]\]. The validity and reliability of outpatient diagnoses recorded in claims data are limited \[[@pone.0232969.ref024], [@pone.0232969.ref025]\]. Thus, we decided to exploit the information on prescribed medications as a surrogate for diseases/disorders associated with increased fracture risk. Henceforth, we refer to these predictors as "drug-related risk factors".

Analysis methods {#sec011}
----------------

We applied the superlearner (SL) approach \[[@pone.0232969.ref017], [@pone.0232969.ref018], [@pone.0232969.ref026]\] to predict the occurrence of hip fracture within 4 years of baseline. Superlearning is an ensemble machine learning method for choosing via cross-validation the optimal weighted combinations of the predictions made by a set of candidate algorithms. It does not require an a priori selection of algorithms, but is technically capable of selecting the best set of algorithms from multiple options and integrating the results from the relevant ones. Candidate algorithms can be both parametric and non-parametric and each algorithm is k-fold cross-validated on a dataset to avoid overfitting. We applied 10-fold cross-validation, which divided the dataset into *k = 10* mutually exclusive and exhaustive sets of almost equal size. For each *k* fold, one of the k sets serves as validation set, the others act as training sets. Each algorithm is fitted on the training set to construct the estimators whose performance (so-called risk or squared error) is then assessed in the validation set. Since overly flexible algorithms tend to exploit random variation in the training data to increase accuracy, the performance has to be assessed for the validation dataset. The process is repeated until each set has served both as training and validation sample and predicted values are obtained for all observations. Simple regression techniques may then be used to determine the utility (i.e., the beta-coefficients) of the predicted values of the algorithms for predicting the outcome. Non-significant predictions and their respective algorithms are excluded. A new estimator (so-called SL-estimator) is then generated as a weighted combination of the relevant predictions from the candidate algorithms that yields the smallest squared prediction error. Ideally, the algorithms should be heterogeneous in their statistical properties (i.e., some ought to be parsimonious while others ought to be flexible), in order to allow for different levels of complexity in the data.

Furthermore, we compare our model with extreme gradient boosting (XGBoost). XGBoost is a comprehensive and versatile library, which offers a powerful framework for implementing Gradient Boosted Trees (GBTs). These build an ensemble of multiple weak trees (e.g., trees with few decision rules) in sequence, thereby allowing each tree to learn and improve upon the previous trees. It is a state of the art machine learning approach that outperformed traditional techniques in various settings \[[@pone.0232969.ref027], [@pone.0232969.ref028]\]. Therefore, it is currently the best option for a gold standard comparison. Details on the parameter values of the final model and how they were obtained can be found in the supplement.

Candidate learning algorithms for the superlearner {#sec012}
--------------------------------------------------

We considered the following candidate learning algorithms: Logistic regression using forward and backward variable selection (main effects only) \[[@pone.0232969.ref029]\], random forests \[[@pone.0232969.ref030]\], support vector machines (SVM) \[[@pone.0232969.ref031]\] and RUS (random undersampling)---Boost with SVM as learner \[[@pone.0232969.ref032], [@pone.0232969.ref033]\]. Additionally, we considered the stepwise logistic regressions with an alternative model specification that included two-way interaction between age and all other predictors as well as sex and all other predictors. Random forests (RF) combine predictions from all regression or classification trees that have been fitted to a data set. The growth of each tree is based on a random process, which uses a randomly drawn subsample and a random subset of the available features for each splitting decision. Thus, the method requires a large number of individual trees to detect the most important variables and make accurate predictions.

SVM aim to classify cases by constructing a hyperplane that achieves the best partitioning of the data by maximizing the margin between the closest points of two classes. Whenever a linear separator cannot be found, the observations are mapped to a higher-dimensional space using a (non-)linear kernel function to enable linear separation \[[@pone.0232969.ref034]\].

RUSBoost, a hybrid approach designed for imbalanced data problems, combines random undersampling and boosting. The latter generates a strong classifier from a number of so-called weak learning algorithms. These weak learners ought to achieve accuracy just above random chance. We chose the AdaBoost.M2-algorithm \[[@pone.0232969.ref035]\] using a support vector machine with a linear kernel as weak learner. AdaBoost applies a weak learner repeatedly to predict the most fitting class. A set of plausibility values for the possible classes is assigned to each case. The weak learners are evaluated using a loss-function that penalizes different types of misclassification. With each iteration, the loss-function values are updated allowing the algorithm to focus on classes which are particularly difficult to distinguish from the correct class. By addressing these difficult cases, AdaBoost.M2 can outperform other methods in imbalanced datasets, where the correct classification of the minority class is often most challenging. An overview of the algorithms is provided in the electronic supplement ([S1 File](#pone.0232969.s001){ref-type="supplementary-material"} of S1 Table).

Random undersampling {#sec013}
--------------------

The dataset was divided into a training (80%) and a validation dataset (20%). For the training set, random undersampling methods were applied to address that most algorithms try to minimize the overall error rate. In our context, predicting exclusively non-fractures would already result in an extremely low error rate, although the predictions would practically be useless. Thus, although random undersampling is associated with a loss of information \[[@pone.0232969.ref036]\], it may improve the classifiers' performance with regard to the AUC \[[@pone.0232969.ref037]\] by reducing the overwhelming influence of the majority class in imbalanced datasets. In addition, it has been shown that methods that rely on random undersampling in an imbalanced setting are often more simple, faster, and comparable (if not better) in their performance compared to other sampling methods \[[@pone.0232969.ref033]\]. In a first step, a one-sided selection method was used \[[@pone.0232969.ref038]\] that eliminates cases from the majority class (*no fracture*) while keeping all cases from the minority class (*fracture*). In a second step, random undersampling was performed until the ratio of minority to majority class was 3:7. Given that the base rate of hip fractures in the original dataset was only about 3%, complete balance, (i.e., a ratio of 1:1) was deemed too expensive, because the number of cases lost due to undersampling substantially increases the more balanced the ratio becomes. The final training set resulted in 20,456 individuals. Each candidate algorithm was implemented using the (undersampled) dataset. The predictors considered in the analyses are listed in [Table 1](#pone.0232969.t001){ref-type="table"}.

10.1371/journal.pone.0232969.t001

###### Characteristics of study population (n = 288,086).

![](pone.0232969.t001){#pone.0232969.t001g}

  Characteristic                                                                                           No.                \%
  -------------------------------------------------------------------------------------------- ----------- --------- -------- -------
  Female gender                                                                                            140,709            48.8%
  Age (at baseline), years                                                                     Mean (SD)   75.67     (6.20)   
  Hip fracture within the 4 year follow-up                                                                 7,644              2.7%
  Patients without a hip fracture within the 4 year follow-up                                              280,442            97.3%
  Patients without a hip fracture within the 4 year follow-up who were not lost to follow-up               231,578            80.4%
  Prior osteoporotic fracture (2 years)                                                                                       
      all                                                                                                  7,032              2.4%
      minor                                                                                                2,580              0.9%
      major                                                                                                4,864              1.7%
      hip                                                                                                  1,854              0.6%
  Medication (within the seven months before baseline):                                                                       
      Antiparkinson agents                                                                                 7,050              2.4%
      Anticonvulsants/Antiepileptics                                                                       8,313              2.9%
      Aromatase inhibitors                                                                                 1,295              0.4%
      Antidiabetic agents                                                                                  36,782             12.8%
      Proton pump inhibitors                                                                               55,770             19.4%
      Antidementives                                                                                       2,509              0.9%
      Drugs for obstructive airway diseases                                                                29,616             10.3%
      Bisphosphonates                                                                                      9,451              3.3%
      Bisphosphonate combinations                                                                          1,831              0.6%
      Raloxifene                                                                                           304                0.1%
      Antidepressants, psycholeptics, and their combinations                                               42,849             14.9%
      Gestagens, estrogens, and their combinations                                                         10,030             3.5%
      Glucocorticoids (systemic), and combinations with antiphlogistics/antirheumatics                     20,648             7.2%
      Anti-inflammatory and antirheumatic agents                                                           2,299              0.8%
      Calcium, vitamin D and analogues, and combinations                                                   9,798              3.4%
      Thyreostatic agents                                                                                  3,632              1.3%
      GnRH analogues, antiandrogens                                                                        3,775              1.3%
      Ophthalmic agents                                                                                    33,351             11.6%
      Anticholinergic agents                                                                               7,786              2.7%
      Tamsulosin                                                                                           20,787             7.2%
  Lost to follow-up:                                                                                                          
      Total (death within four years, other reasons)                                                       51,476             17.9%
      Death within the first year                                                                          7,721              2.7%
      Death within twoyears                                                                                17,492             6.1%
      Death within three years                                                                             28,957             10.1%
      Death within four years                                                                              40,527             14.1%

GnRH, Gonadotropin-releasing hormone.

We applied the SL approach (as described above) to select the best combination of these algorithms specifying 10-fold cross-validation. Superlearner is implemented in the R package Super Learner \[[@pone.0232969.ref039]\]. All analyses were carried out using R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).

Evaluating algorithm performance {#sec014}
--------------------------------

All candidate algorithms that enter the superlearner were fitted on the entire training dataset and their performance further assessed using the validation dataset. To evaluate classification performance the mean squared errors (MSE) and AUC values were calculated for both the individual algorithms and the superlearner. AUC is used to evaluate overall prediction accuracy. Model calibration was assessed with the Hosmer-Lemeshow statistic \[[@pone.0232969.ref029]\]. Moreover, we used calibration plots, which plot actual fracture percentages against those predicted by the algorithms for various risk quantile to assess (lack of) fit. Due to random undersampling, the base rate in the training set differed from the base rate in the validation set. Therefore, the predicted probabilities were adjusted before using them for model calibration in order to avoid overestimation of the proportion of fracture events \[[@pone.0232969.ref040]\].

Results {#sec015}
=======

Descriptive analysis {#sec016}
--------------------

A summary of variables used in the analysis is presented in [Table 1](#pone.0232969.t001){ref-type="table"}. Of the 288,086 individuals that were originally included in the sample, 20,456 were used during training and 57,618 in the validation dataset. Mean age of the original sample was 75.7 years (SD: 6.2), 48.8% were female. About 3% sustained a hip fracture during follow-up. 2.4% of the sample had any prior clinically diagnosed osteoporotic fracture and 0.6% had a prior diagnosed hip fracture. Drug-related risk factors affecting the largest percentage of the sample were proton pump inhibitors (19.4%), followed by antidepressants, psycholeptics, and their combinations (14.9%), antidiabetic agents (12.8%), ophthalmic agents (11.6%), and drugs for obstructive airway diseases (10.3%).

Model performance {#sec017}
-----------------

The performance of the superlearner was similar to other individual algorithms used in the analysis. With regard to the Brier score, the superlearner algorithm for predicting hip fracture improved upon random forests by 6%. The superlearner performed very similarly to RUSBoost with only marginal improvement in Brier score. Compared to logistic regression the superlearner performed slightly worse with respect to brier score. All algorithms achieved moderate discriminatory performance, with AUC values ranging from 0.650 for SVM to 0.704 for logistic regression in the validation set and from 0.660 for SVM to 0.721 for superlearner in the training set. The superlearner (AUC 0.698, 95% CI 0.684--0.711) was slightly outperformed by logistic regression (AUC 0.704, 95% CI 0.691--0.718) and XGBoost (AUC 0.703, 95% CI 0.689--0.716) in the validation set. In the training set, the superlearner and XGBoost performed better than the candidate algorithms regarding their discriminatory ability, with an AUC of 0.722 (95% CI 0.714--0.729) for the superlearner and an AUC of 0.725 (95% CI 0.718--0.733) for XGBoost. Results are shown in [Table 2](#pone.0232969.t002){ref-type="table"}. Furthermore, we provide information on the number of false negatives and false positives as well as the corresponding rates for the superlearner and our benchmark model XGBoost in the [S1 File](#pone.0232969.s001){ref-type="supplementary-material"} of S1 and S2 Figs.

10.1371/journal.pone.0232969.t002

###### Brier score and AUC for each algorithm.

![](pone.0232969.t002){#pone.0232969.t002g}

                                                                                                                  Validation   Training                 
  -------------------------------------------------------------- ------------------------------------------------ ------------ ---------------- ------- ----------------
  Logistic regression with forward selection                     0.0251                                           0.704        (0.691--0.718)   0.713   (0.705--0.720)
  Logistic regression with forward selection and interactions    0.0265                                           0.698        (0.685--0.712)   0.712   (0.705--0.720)
  Logistic regression with backward selection                    0.0261                                           0.704        (0.690--0.717)   0.713   (0.705--0.720)
  Logistic regression with backward selection and interactions   0.0267                                           0.695        (0.681--0.708)   0.714   (0.706--0.721)
  Random forest                                                  0.0268                                           0.685        (0.671--0.699)   0.686   (0.678--0.694)
  Support vector machines                                        0.0252 [^a)^](#t002fn002){ref-type="table-fn"}   0.650        (0.635--0.666)   0.660   (0.651--0.668)
  RUSBoost                                                       0.0254                                           0.702        (0.688--0.715)   0.711   (0.703--0.718)
  Superlearner                                                   0.0259                                           0.698        (0.684--0.711)   0.722   (0.714--0.729)
  XGBoost                                                        0.0251                                           0.703        (0.689--0.716)   0.725   (0.718--0.733)

CI, confidence interval.

^a)^ Brier score was calculated by transforming the support vector machine output to probabilities using a sigmoid link function.

Actual and predicted fracture percentages are shown in [Fig 1](#pone.0232969.g001){ref-type="fig"}. The calibration plot indicates that the superlearner (right panel) underestimated actual fracture probability to some extent. Thus, the fit for the superlearner was only moderate (Chi-Square = 154.75, p\<0.001). However, for logistic regression, which performed best as regards Brier score and AUC in the validation set, calibration was good (Chi-Square = 15.14, p = 0.06).

![Calibration plots for logistic regression (left panel) and superlearner (right panel).\
The plots show the calibration for the validation dataset. We grouped the n = 57,618 individuals in the validation dataset according to their respective 5% risk quantile as predicted by either the logistic regression or the superlearner. For each quantile group, we plotted the predicted proportion of S72.0-S72.2 fractures against the actual proportion of S72 fractures.](pone.0232969.g001){#pone.0232969.g001}

Components of risk {#sec018}
------------------

The output of machine learning techniques is not as readily interpretable as the significance tests for the coefficients of parametric techniques. The performance regarding prediction accuracy can easily be assessed, while the importance of specific variables cannot be determined without additional analysis. Thus, we used the logistic model (with forward selection) to determine which variables were important for fracture prediction. In particular, female gender, older age, and prior fracture history were associated with a higher probability of sustaining hip fractures. Also, several medical conditions (operationalized by medication use) such as Parkinson's disease, dementia, or diabetes as well as the use of glucocorticoids were significantly associated with higher fracture probability ([Table 3](#pone.0232969.t003){ref-type="table"}).

10.1371/journal.pone.0232969.t003

###### Coefficients of multivariable logistic regression to predict hip fracture.

![](pone.0232969.t003){#pone.0232969.t003g}

  Predictor                                                               β value                                           SE      p
  ----------------------------------------------------------------------- ------------------------------------------------- ------- -------
  Intercept                                                               -9.216[\*\*\*](#t003fn002){ref-type="table-fn"}   0.204   0,000
  Age (effect for each additional year)                                   0.101[\*\*\*](#t003fn002){ref-type="table-fn"}    0.003   0,000
  Female gender                                                           0.628[\*\*\*](#t003fn002){ref-type="table-fn"}    0.034   0,000
  Prior osteoporotic fracture (2 years)                                   0.402[\*\*\*](#t003fn002){ref-type="table-fn"}    0.099   0,000
  Prior osteoporotic hip fracture (2 years)                               0.635[\*\*\*](#t003fn002){ref-type="table-fn"}    0.175   0,000
  Antidiabetic agents                                                     0.276[\*\*\*](#t003fn002){ref-type="table-fn"}    0.047   0,000
  Antiparkinson agents                                                    0.385[\*\*\*](#t003fn002){ref-type="table-fn"}    0.092   0,000
  Antidementives                                                          0.482[\*\*\*](#t003fn002){ref-type="table-fn"}    0.138   0,000
  Anticonvulsants/Antiepileptics                                          0.270[\*\*](#t003fn003){ref-type="table-fn"}      0.087   0,002
  Proton pump inhibitors                                                  0.109[\*\*](#t003fn003){ref-type="table-fn"}      0.040   0,007
  Antidepressants, psycholeptics, and their combinations                  0.096[\*](#t003fn004){ref-type="table-fn"}        0.044   0,028
  Anticholinergic agents                                                  0.208[\*](#t003fn004){ref-type="table-fn"}        0.091   0,022
  Antiinflammatory and antirheumatic agents                               0.338[\*](#t003fn004){ref-type="table-fn"}        0.167   0,042
  Aromatase inhibitors                                                    0.319                                             0.218   0,144
  Thyreostatic agents                                                     -0.182                                            0.130   0,159
  Glucocorticoids, and combinations with antiphlogistics/antirheumatics   0.198[\*\*\*](#t003fn002){ref-type="table-fn"}    0.061   0,001
  GnRH analogues, antiandrogens                                           0.338[\*\*](#t003fn003){ref-type="table-fn"}      0.125   0,007
  Gestagens, estrogens, and combinations                                  -0.244[\*\*](#t003fn003){ref-type="table-fn"}     0.091   0,008
  Bisphosphonates                                                         0.212[\*\*](#t003fn003){ref-type="table-fn"}      0.082   0,009
  Bisphosphonate combinations                                             0.437[\*](#t003fn004){ref-type="table-fn"}        0.184   0,018

Results are based on the undersampled training dataset. Therefore, a meaningful interpretation can only be given for the effect direction and not the magnitude.

\*\*\* p ≤ 0.001

\*\* p ≤ 0.01

\* p ≤ 0.05. SE---standard error; GnRH---Gonadotropin-releasing hormone.

Discussion {#sec019}
==========

In this study, we developed a prediction algorithm to assess the risk of osteoporotic hip fractures using claims data. The focus was on machine learning techniques including both traditional and newer approaches. In particular, we applied the ensembling superlearner algorithm that can be employed in large administrative claims databases for fracture prediction.

We found the performance of the superlearner algorithm to be similar to the individual algorithms used in the analysis. Although the superlearner did perform no worse than the candidate algorithm in the training set, in the validation set logistic regression, XGBoost and RUSBoost had similar or higher AUCs. Furthermore, when comparing the results of this study with the results of a previous publication, in which we used a Cox proportional hazard model for the prediction of fracture risk \[[@pone.0232969.ref010]\], we only find negligible differences in the predictive performance. Consequently, the machine learning approach offers no benefits in this context when compared to traditional approaches. Regarding our data source, we found that predictions based on german claims data are considerably worse than predictive models that take advantage of clinical information such as bone mineral densities and biochemical glucose measurements. In Denmark, a recent study reported an AUC of up to 0.92 for hip fracture predictions, which highlights the benefit of using a National Patient Registry that contains clinical and laboratory information for risk prediction \[[@pone.0232969.ref041]\].

Notably, in several datasets the superlearner increased performance when compared to its candidate algorithms \[[@pone.0232969.ref018]\]. Nevertheless, we found multiple studies, who correspondingly found no major differences between the supe learner and more traditional methods or even somewhat worse performance \[[@pone.0232969.ref015], [@pone.0232969.ref042]\].

In this study, the slightly poorer calibration of the superlearner may be partly due to the fact that the algorithm did not estimate probabilities. Thus, the adjustment method proposed by Saerens et al. \[[@pone.0232969.ref040]\] may have been imperfectly suited for incorporating the bias due to random undersampling.

As it is recommended to decide upon input variables, candidate algorithms, and their specification before running the analysis \[[@pone.0232969.ref011]\], we considered risk factors commonly included in fracture risk assessment tools that were also available in claims data. To help to achieve a better understanding of important risk factors, we reported the output of a logistic regression analysis and report a variable importance plot of XGBoost in the supplement. However, caution is needed in interpreting the results of an exploratory logistic regression with a forward selection method, because it exploits random variation. Nonetheless, it appeared that next to some drug-related risk factors, risk factors such as gender, prior fracture, and age noticeably contributed to risk prediction. Thus, the model performance was mainly dependent on few predictors that are known to be important. This is in line with other studies finding so simple models consisting of fewer predictors e.g., age, gender, and prior fracture perform as well as more complex models in predicting fracture \[[@pone.0232969.ref043], [@pone.0232969.ref044]\].

The fact that drug-related risk factors had limited additional explanatory power in this study may partly explain moderate performance of the superlearner. Our choice to employ a superlearner approach in this study was driven by the effectiveness of the technique in other studies \[[@pone.0232969.ref012], [@pone.0232969.ref018]\], the low base rate of hip fractures in our data and the relatively large number of potential predictors we initially considered. It is still not fully understood whether and when complex ensemble machine learning techniques offer real value over traditional methods in clinical prediction tasks \[[@pone.0232969.ref045]\]. We agree with previous findings on this question that a strong non-linear relationship between the predictors and the response appears to be an important prerequisite \[[@pone.0232969.ref046]\] and that the signal-to-noise ratio ought to be high \[[@pone.0232969.ref047]\].

Strengths and limitations {#sec020}
-------------------------

Major strengths of the study are the large number of observations and the rich set of potential risk factors derived from administrative claims data. This allowed us to apply powerful machine learning methods for fracture prediction, which have the potential to take advantage of complex interactions and unknown non-linear effects. Moreover, we performed a systematic fracture outcome ascertainment based on ICD-10 hospital diagnoses. Hence, outcome misclassification, which often is an issue in ambulatory settings, should be low as nearly all people with hip fractures are admitted to hospital.

Since we were faced with highly imbalanced data as regards fracture events, we employed random undersampling to mitigate the issue that some algorithms perform poorly in imbalanced datasets. However, we are well aware that there are alternative measures for dealing with this issue. For instance, we could have applied oversampling, which would entail replicating the minority samples until fracture and non-fracture events are well-balanced. In our study, this would require n = 120,189 minority cases--i.e., we would need to replicate each minority case almost 16 times--to reach the desired ratio of 3:7. Drawing each minority case that frequently substantially increases the risk of overfitting. Moreover, given our sample size, oversampling would drastically increase the computational runtime and the probability for running out of memory. Consequently, we decided on random undersampling, although randomly drawing from the majority sample sometimes discards informative cases \[[@pone.0232969.ref048], [@pone.0232969.ref049]\] and it can distort significance tests and the magnitude of the parameter estimates--i.e., the obtained estimates and p-values ought to be interpreted with caution. In the future, it might be a promising alternative to optimize other metrics than the global classification accuracy, because non-decomposable functions such as the F-Score or precision are more natural choices for imbalanced data that do not require random over- or undersampling \[[@pone.0232969.ref050]\]. Unfortunately, current implementations are limited to using these functions as evaluation criteria, which does not enable parameter optimization.

We recognise that the ascertainment of (co-)morbidities proves a challenge in (administrative) ambulatory claims data. The lack of reliability of diagnosis coding in the ambulatory setting has been repeatedly shown \[[@pone.0232969.ref024], [@pone.0232969.ref025]\]. Therefore, we solely considered drug exposure as surrogate variable, but no ambulatory ICD-10 diagnoses to identify and define conditions that have been associated with increased fracture risk such as Parkinson\'s disease \[[@pone.0232969.ref051]\]. Prescribed medications whose ATC Classification starts with N04 are almost exclusively used to manage Parkinson\'s disease and are therefore a reliable indication for that particular disorder. This prescription based measure was chosen, because using the most reliable source of information (i.e., hospital diagnoses) would have introduced considerable bias, because in this case only individuals with a hospital stay would have been recorded. In addition, we included medications that have multiple indications but were consistently associated with fracture risk in previous studies such as psychotropic drugs \[[@pone.0232969.ref052]\].

Only risk factors available in administrative claims data could be considered. Risk factors drawn from self-reported data, registries/EHR such as smoking, alcohol use or BMI were not accounted for. Such information is either unavailable or cannot be retrieved from administrative claims data without bias. Including such additional risk factors might have contributed to better performance of the algorithms.

In this study, we assessed a relatively long follow-up period, because we needed to identify a sufficient number of fracture events (the incidence rate of hip fracture was only 0.6% within the first year). As a result, we were able to apply data hungry machine learning techniques \[[@pone.0232969.ref053]\]. Nonetheless, this approach had some disadvantages. First, almost 18% of our sample were not observed until the end of the 4 year follow-up period. In spite of that we decided to not exclude patients that switched to another statutory health insurance or passed away during the follow-up period, because this information would not be available in a prediction model that is implemented to identify insurees who will be at risk in the future. Second, we are aware that recently assessed prescription based risk factors have a higher predictive value \[[@pone.0232969.ref054]\]. Thus, the long follow-up period could have negatively influenced the model performance.

Finally, our data were derived from only one health insurer and may not be representative for the whole German population. Compared with persons insured by other health insurance providers, persons insured at this particular health insurer represent those living in more rural regions and working or having worked in the agricultural (incl. forestry and horticulture) sector. This may have influenced the number of hip fractures because lower rates for both hip fractures and fractures at other sites typically associated with osteoporosis have been reported in rural populations \[[@pone.0232969.ref055], [@pone.0232969.ref056]\].

Conclusion {#sec021}
==========

In general, the performance of the superlearner was similar to the included individual algorithms used in the analysis. It showed good discrimination in the training data set, but poorer discrimination and calibration in the validation set compared to the candidate algorithms. The lack of substantive difference between these methods does not speak against the superlearner per se. In other cases, the superlearner has proven to perform at least as well or even better than its candidate methods. In our case, however, any of the methods we included, and in particular simpler ones, may be used for these data to predict fracture risk.
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Reviewer \#1: The authors are presenting results on the prediction of osteoporotic hip fractures using various machine leaning techniques (logistic regression with forward selection, random forest, support vector machine, adaptive boosting with random undersampling) and compared the individual results to a meta learner/ super learner making use of all base learner. The data base consists of administrative claims from a German health insurance including more than 280000 individuals without the need for basic care. Hip fracture was recorded in a 4-year follow up and possible predictors entered the models from the baseline (e.g. age, gender, prior fractures, drugs). The authors achieved an AUROC of about 0.7.

The authors presented their results in an intelligible fashion and the paper is well written. It contains necessary data description and supporting information on the methods (with packages used in R) to allow reproducibility. The methods are well summarized.

Besides the good overall impression, I have some questions and remarks which should be addressed and which would further improve the paper:

1\. Data

a\) It could be of importance to add the working status at baseline as another predictor, since you are including individuals aged 65 years and older. Furthermore, I advise to include the number of drugs prescribed per person as a continuous variable as well as the the number of drugs related to osteoporosis and number of drugs not related to osteoporosis.

b\) Are there other exclusion criteria than described? I am thinking of individuals passing away during the 4-year follow-up, individuals who switched to another health insurance during the follow-up (you only wrote, that you excluded cases with incomplete 24-month pre-baseline).

c\) Is your response variable the all-cause hip fracture or do you distinguish between osteoporotic and non-osteoporotic hip fractures?

d\) It would be nice to see the prediction performance on time scales of the outcome variable: hip-fracture occurring e.g. within 6 months, 12 months, 24 months and 48 months, since the drug prescriptions could have a higher predictive value within the first 6 months than within 48 months.

2\. Methods

a\) You should think of including other boosting methods such as XGBoost and Gradient boosting to allow a better comparison of current (state-of-the-art) ML techniques.

b\) Under-sampling should be compared with other methods such as Up-sampling (e.g. with SMOTE). Do you also repeated the random sampling to create multiple training sets?

c\) Have you tried to drop the sampling strategy and tried to optimize the F1-Score instead? The F1-Score is independent of balancing. Please do add the numbers of false positive and false negative in the validation set.

d\) Think of including interactions (with age or gender) in your regression models.

Line-by-line comments on the manuscript:

65: Germany does not have one of the highest hip-fracture rates -- its rather midfield, especially in the 10y probability of major fractures. Better refer to the high rates in Northern Europe (Denmark, Sweden, Norway).

66: In the original paper it is 610,000.

68: Punctuation error before reference number

82: Cox proportional hazards regression

86-87: What do you mean with 'advanced' ML methods -- please name those

87: 'may have the potential' -- How large is the expected effect on the AUC? Please refer to other papers on disease predictions where those new methods outperformed classical approaches.

97: The present study is

109: Is this the LKK (Landwirtschaftliche Krankenkasse)? I havn't found 'German agricultural sickness fund'.

143: How many folds have you used? Define k.

167: SVM already abbreviated

170: Which kernel have you used?

171: RUSBoost is an abbreviation, please add also the full name.

196: Why do you use 3:7 sampling? I there any recommendation giving in the literature?

219: I just see 20,456 individuals used for training and 20% of 288,000 for testing. To the analysis did not include 288,086 individuals.

221: Please write the number in numeric form: 2.4%

223: 0.6% of all samples

234: Please add columns with the number of individuals with and without 4yr-hip-fracture to allow univariable comparisons (and probably important for inclusion in meta-analysis).

249: The MSE for SVM can be calculated in R using caret, see <https://www.quora.com/How-can-I-calculate-the-mean-square-error-MSE-for-SVM-in-R>

257: Suggested section title: Predictors

267: Table header suggestion: Coefficients of multivariable logistic regression to predict hip fracture

267: Please add the p-values.

267: Please add the unit of 'Age' to make clear that this is the beta-coefficient for 1 year difference.

282: Full stop after algorithms and add citation

293: I disagree, this is not computationally expensive -- it can be directly extracted from the model

302: Please compare your results with described performances in the literature, ... AUC in model with bone density information is 0.82 ...

306: Please add citation

313: If your intention was to find complex interaction, why do you just present results from the logistic regression without any interaction?

319: I don't see any memory problems arising from a data frame with 20000 individuals and probably less than 100 features.

359: software

Reviewer \#2: Review for manuscript titled with "Osteoporotic hip fracture prediction from risk factors available in administrative claims data -- a machine learning approach"

This retrospective study applied several algorithms , including super learner method to predict osteoporotic hip fracture using administrative claims data and found out the the super learner achieved similar predictive performance compared to other algorithms

Introduction:

1\. Well-written

2\. The sentence started from the line 80 " Moreover, claims data in Germany ......within the observational period" was not clear, please clarify

Methods:

1\. In the paragraph of "sample", the baseline for the study was not well defined. For an example, in line 108, the baseline is April, 1 2010 and pre baseline is 24 months. Were patients allowed to enter the cohort after April, 1, 2010?

2\. In the paragraph of " Outcome variable", "hip fracture occurring within 4 years of baseline" was the outcomes of interest? Please clarify baseline and prebaseline.

3\. It was not clear whether the patients were allowed to have multiple fractures or only the first one.

4\. Please explain why some variables were evaluated using 2 years pre baseline, but some factors were evaluated in the seven month before baseline.

5\. This paper used prescribed medications as a surrogate for diseases associated with fracture risk, however, many medications have multiple indications. Has these surrogates been validated yet?

6\. Suggest to also use logistic regression backward as it is has been reported more conservative

7\. The analysis section is clear and well written

Results:

1\. Suggest the authors to add the time period for the medications in table 1

2\. Please also provide the characteristics for patients risk during the follow up time.
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We refer to the uploaded word document for a better formatted version of these responses.

Comments of Reviewer 1)

a\) It could be of importance to add the working status at baseline as another predictor, since you are including individuals aged 65 years and older.

Furthermore, I advise to include the number of drugs prescribed per person as a continuous variable as well as the the number of drugs related to osteoporosis and number of drugs not related to osteoporosis.

We agree that the employment status could be of importance. Unfortunately, this information could not be provided by our contract partner (i.e. the statutory health insurance SVLFG).

Regarding the suggestions to add the number of drugs prescribed, we believe that this would not be in line with our methodological decision to focus on risk factors that were previously shown or suggested to be associated with osteoporotic fractures in the literature or in validated fracture tools such as QFracture and FRAX.

The list of included drugs was discussed and further refined with a clinical expert (Kilian Rapp) and a trained pharmacologist (Sarah Mächler) to ensure face validity with regard to clinical relevance and appropriate Anatomical Therapeutic Chemical (ATC) classification. While including a larger set of predictors as well as aggregates of existing ones may improve model performance, we argue that limiting the set of predictors to those with a strong theoretical foundation improves transparency and reduces the risk of overfitting (1).

b\) Are there other exclusion criteria than described? I am thinking of individuals passing away during the 4-year follow-up, individuals who switched to another health insurance during the follow-up (you only wrote, that you excluded cases with incomplete 24-month pre-baseline).

The prediction model was designed as a way for insurance companies to predict at risk groups. Successfully identifying these groups would enable efficient prevention. Consequently, it is important to not select individuals based on how they will develop in the follow-up period, because the future development (e.g., whether patients will pass away or switch to another health plan) would not be known when the prediction tool is implemented.

However, we agree that it is important to report the number of patients that were lost-to-follow-up due to death or other reasons, because the amount of censoring affects model performance. Therefore, we added this information in table 1. We also included the number of patients that die within the first, second, third and fourth year.

In addition, we discuss the issue of decreased model performance in a new section referenced in our answer

to bullet point (d).

c\) Is your response variable the all-cause hip fracture or do you distinguish between osteoporotic and non-osteoporotic hip fractures?

All S72 femur fracture were assessed. We clarified this under the section: Outcome Variable

The outcome variable was the first hip fracture -- both osteoporotic and non-osteoporotic -- occurring within 4 years after the index date -- i.e. between April 1 2010 and 31 March 2014.

d\) It would be nice to see the prediction performance on time scales of the outcome variable: hip-fracture occurring e.g. within 6 months, 12 months, 24 months and 48 months, since the drug prescriptions could have a higher predictive value within the first 6 months than within 48 months

We used a relatively long follow-up period, because hip fracture occur rather rarely. The incidence rate was very low. For instance, within the first 6 month we observed an incidence rate of 0.27% for the sample. In order to have a sufficient number of minority cases (i.e. fracture events), it was necessary to assess a relatively long follow-up period. However, we agree that the predictive performance might be better for shorter follow-up periods. We discuss this aspect in our revised discussion.

In this study, we assessed a relatively long follow-up period, because we needed to identify a sufficient number of fracture events (the incidence rate of hip fracture was only 0.6% within the first year). As a result, we were able to apply data hungry machine learning techniques (53). Nonetheless, this approach had some disadvantages. First, almost 18% of our sample were not observed until the end of the 4 year follow-up period. In spite of that we decided to not exclude patients that switched to another statutory health insurance or passed away during the follow-up period, because this information would not be available in a prediction model that is implemented to identify insurees who will be at risk in the future. Second, we are aware that recently assessed prescription based risk factors have a higher predictive value (54). Thus, the long follow-up period could have negatively influenced the model performance.

e\) You should think of including other boosting methods such as XGBoost and Gradient boosting to allow a better comparison of current (state-of-the-art) ML techniques.

Thank you for this suggestion. We decided to implement XGBoost as our benchmark model and added a paragraph on the method:

Furthermore, we compare our model with extreme gradient boosting (XGBoost). XGBoost is a comprehensive and versatile library, which offers a powerful framework for implementing Gradient Boosted Trees (GBTs). These build an ensemble of multiple weak trees (e.g. trees with few decision rules) in sequence, thereby allowing each tree to learn and improve upon the previous trees. It is a state of the art machine learning approach that outperformed traditional techniques in various settings (2, 3). Therefore, it is currently the best option for a Gold-Standard comparison. Details on the parameter values of the final model and how they were obtained can be found in the supplement.

f\) Under-sampling should be compared with other methods such as Up-sampling (e.g. with SMOTE). Do you also repeated the random sampling to create multiple training sets?

The main tradeoff between random under- or oversampling is that oversampling may lead to overfitting as it makes exact copies of the minority samples, while undersampling may discard potential useful majority samples (4). Moreover, oversampling substantially increases computational cost (5).

Given the large sample size, we assumed that overfitting would be a larger issue than a non-representative majority sample. Moreover, we were constrained by our computational resources, which were not sufficient to compare various sampling strategies and parameter settings. Comparing multiple algorithms, using an ensembling strategy and being able to use 10-fold cross validation on our training sample was a top priority. As these methods would be computationally very expensive in an up-sampling context (given our large sample size) or in a setting where multiple training sets would have been created, we decided against it.

However, we added this limitation to our discussion:

Since we were faced with highly imbalanced data as regards fracture events, we employed random undersampling to mitigate the issue that some algorithms perform poorly in imbalanced datasets. However, we are well aware that there are alternative measures for dealing with this issue. For instance, we could have applied oversampling, which would entail replicating the minority samples until fracture and non-fracture events are well-balanced. In our study, this would require n=120,189 minority cases -- i.e. we would need to replicate each minority case almost 16 times -- to reach the desired ratio of 3:7. Drawing each minority case that frequently substantially increases the risk of overfitting. Moreover, given our sample size, oversampling would drastically increase the computational runtime and the probability for running out of memory. Consequently, we decided on random undersampling, although randomly drawing from the majority sample sometimes discards informative cases (4, 5). Furthermore, it can distort significance tests and the magnitude of the parameter estimates -- i.e. the obtained estimates and p-values ought to be interpreted with caution. In the future, it might be a promising alternative to optimize other metrics than the global classification accuracy, because non-decomposable functions such as the F-Score or precision are more natural choices for imbalanced data that do not require random over- or undersampling (6). Unfortunately, current implementations are limited to using these functions as evaluation criteria, which does not enable parameter optimization.

g\) Have you tried to drop the sampling strategy and tried to optimize the F1-Score instead? The F1-Score is independent of balancing.

The F1-Score is a non-decomposable loss functions -- i.e. the loss on a set of points cannot be expressed as the sum of losses on individual data points. This makes it a lot more difficult to implement the F1-Score as a loss function (6). To date, there is no r package that accomplishes this for the algorithms used in our super learner. Instead, the F1-Score is mainly used as an evaluation metric. XGboost has an option to implement early stopping based on the F1-Score, which could potentially help to find a model that performs better on the F1-Score. However, when we implemented this model for our data, it did not converge or pick up any parameter trends towards a global minimum.

h\) Please do add the numbers of false positive and false negative in the validation set.

We added graphs in the supplement that show the development of the proportion and number of false positives and negatives in the validation dataset as a function of the chosen cutoffs for the superlearner model and XGBoost.

We refer to these graphs in the revised manuscript:

Results are shown in Table 2. Furthermore, we provide information on the number of false negatives and false positives as well as the corresponding rates for the superlearner and our benchmark model XGBoost in the supplemental figures 1 and 2.

i\) Think of including interactions (with age or gender) in your regression models.

Thank you for this suggestion. We added a logistic regression with these interactions as another candidate algorithm.

j\) 65: Germany does not have one of the highest hip-fracture rates -- its rather midfield, especially in the 10y probability of major fractures. Better refer to the high rates in Northern Europe (Denmark, Sweden, Norway).

We changed the sentence to:Some of the highest hip fracture rates are seen in Europe and particularly in northern Europe -- i.e. Denmark, Sweden and Norway.

k\) 66: In the original paper it is 610,000.

Thank you for pointing that out. We changed the incident number.

l\)

68: Punctuation error before reference number

82: Cox proportional hazards regression

Thank you for pointing that out. We corrected these mistakes.

m\)

86-87: What do you mean with 'advanced' ML methods -- please name those

We refer to methods which have proven useful over time in kaggle competitions etc. (e.g. neural networks, ensembling strategies or gradient boosting).

Only recently, advanced machine learning methods -- e.g., neural networks, ensembling strategies or gradient boosting -- have begun to be used for clinical prediction models (7, 8).

n\)

87: 'may have the potential' -- How large is the expected effect on the AUC? Please refer to other papers on disease predictions where those new methods outperformed classical approaches.

This is a rather difficult question to answer, because most studies that use machine learning do not compare their chosen algorithm to traditional approaches. In addition, the expected increase in the AUC depends on the number of interactions and non-linear relationships not captured by traditional approaches.

Nonetheless, we reviewed recent comparisons and referenced these papers in the introduction:

To date, it is difficult to estimate the potential of these techniques, because they are rarely systematically compared to traditional approaches. Furthermore, the utility largely depends on where and how they are employed. Miotto, Li (9) recently showed that unsupervised feature learning based on neural networks can significantly boost the consecutive disease classification from an AUC of 0.632 (worst alternative) to 0.773. However, other studies report rather small improvements in the AUC of around 3% when comparing modern machine learning techniques to traditional approaches (10, 11). Thus, we believe that it is important to examine whether applying more complex algorithms as opposed to traditional regression techniques offers incremental value in various contexts to learn when this additional effort amounts to meaningful improvements.

o\)

97: The present study is

Thank you for pointing this out.

p\)

109: Is this the LKK (Landwirtschaftliche Krankenkasse)? I havn't found 'German agricultural sickness fund'.

The study was based on data provided by the German social insurance for agriculture, forestry and horticulture (Sozialversicherung für Landwirtschaft, Forsten und Gartenbau, SVLFG). The LKK was integrated in the SVLFG in spring of 2013.

We added this information under the sample section:

All data were provided by the German agricultural sickness fund Sozialversicherung für Landwirtschaft, Forsten und Gartenbau (SVLFG).

q\)

143: How many folds have you used? Define k.

K=10.

We applied 10-fold-cross-validation, which divided the dataset into k=10 mutually exclusive and exhaustive sets of almost equal size.

167: SVM already abbreviated

Thank you. We use the abbreviation in the revised version.

170: Which kernel have you used?

We used a Gaussian radial basis kernel. This information is provided in the supplement.

171: RUSBoost is an abbreviation, please add also the full name.

We added the full name:

We considered the following candidate learning algorithms: Logistic regression using forward variable selection (12), random forests (13), support vector machines (SVM) (14), RUS (random undersampling) - Boost with SVM as learner (15, 16).

r\)

196: Why do you use 3:7 sampling? I there any recommendation giving in the literature?

The exact ratio is arbitrary. To date, to the best of our knowledge, there are no recommendations or simulations on the best possible ratio in imbalanced datasets with different sample sizes. A ratio of 50:50 is ideal for algorithms, because the error on minority samples (i.e. patients with a hip fracture) is as important for minimizing the loss function as the error on the majority sample. However, when random undersampling is applied, this leads to discarding a lot of potentially useful majority samples. If we would have used a 50:50 ratio, our sample size would have decreased to n=12,274 as opposed to n=20,456. The ratio of 3:7 offers both near balance of majority to minority cases and an acceptable loss of information -- given the large number of majority cases.

Other comments:

219: I just see 20,456 individuals used for training and 20% of 288,000 for testing. To the analysis did not include 288,086 individuals.

We agree that the wording was misleading. We changed the sentence:

Of the 288,086 individuals that were originally included in the sample, 20,456 were used during training and 57,618 in the validation dataset. Mean age of the original sample was 75.7 years (SD: 6.2), 48.8% were female.

221: Please write the number in numeric form: 2.4%

223: 0.6% of all samples

We corrected both aspects.

234: Please add columns with the number of individuals with and without 4yr-hip-fracture to allow univariable comparisons (and probably important for inclusion in meta-analysis).

Thank you for pointing that out. We added this information to table 1. In addition, we included the number of patients without a hip fracture within the 4 year follow-up who were not lost to follow-up.

249: The MSE for SVM can be calculated in R using caret, see <https://www.quora.com/How-can-I-calculate-the-mean-square-error-MSE-for-SVM-in-R>

Thank you for this suggestion, the caret package offers several valuable features. However, caret does not evaluate the RMSE for classification models, which completely makes sense. We made a mistake by writing that we calculated the MSE, because we calculated the brier score. It is mathematically really similar, but determines the difference between the estimated probabilities and the actual outcome (1 for events and 0 for non-events). The brier score should not necessarily be reported for support vector machine output, because SVMs do not output probabilities (17). Nonetheless, we used an additional sigmoid function to map the traditional output of the SVM to probabilities (although these are often not well calibrated (18)). We report the brier score based on the transformed output of the SVM. Moreover, we changed the caption und the legend of table 2, so that it is clear that the output of the SVM was transformed before calculating the brier score.

257: Suggested section title: Predictors

We agree that this keyword better captures the content of the section.

267: Table header suggestion: Coefficients of multivariable logistic regression to predict hip fracture

267: Please add the p-values.

267: Please add the unit of 'Age' to make clear that this is the beta-coefficient for 1 year difference.

Thank you for these suggestions. We changed the table accordingly.

282: Full stop after algorithms and add citation

We changed the sentence:

Notably, in several datasets the super learner increased performance when compared to its candidate algorithms (13). Nevertheless, we found multiple studies, who correspondingly found no major differences between the super learner and more traditional methods or even somewhat worse performance (34, 35).

293: I disagree, this is not computationally expensive -- it can be directly extracted from the model

At the time of analysis, it was still relatively difficult to obtain the variable importance plot for certain algorithms, because this functionality had not been implemented yet in all r packages. However, we agree that the caret and XGBoost library make this process easy. Moreover, it is no longer computationally demanding for most algorithms. Nonetheless, it can be time-consuming, because calculating the variable importance requires some-sort of cross validation to obtain an out of the bag sample and iteratively shuffling each predictor variable in the validation dataset during prediction. This can be computationally expensive if the libraries are not written in C++ or Fortran. In addition, the superlearner is constructed after the cross-validation results are obtained, which makes it difficult to assess variable importance during training.

Nonetheless, we agree that this is no longer a valid argument for not providing any variable importance plot. Thus, we added a variable importance from the XGBoost algorithm in the supplement and deleted the paragraph on the computational expense of calculating variable importance.

As it is recommended to decide upon input variables, candidate algorithms, and their specification before running the analysis (11), we considered risk factors commonly included in fracture risk assessment tools that were also available in claims data. To help to achieve a better understanding of important risk factors, we reported the output of a logistic regression analysis and report a variable importance plot of XGBoost in the supplement.

302: Please compare your results with described performances in the literature, ... AUC in model with bone density information is 0.82 ...

We added a section that highlights the utility of having clinical and laboratory information for hip fracture predictions:

Regarding our data source, we found that predictions based on german claims data are considerably worse than predictive models that take advantage of clinical information such as bone mineral densities and biochemical glucose measurements. In Denmark, a recent study reported an AUC of up to 0.92 for hip fracture predictions, which highlights the benefit of using a National Patient Registry that contains clinical and laboratory information for risk prediction (41).

306: Please add citation

We rewrote the section and added citations:

The fact that drug-related risk factors had limited additional explanatory power in this study may partly explain moderate performance of the super learner. Our choice to employ a super learner approach in this study was driven by the effectiveness of the technique in other studies (7, 17), the low base rate of hip fractures in our data and the relatively large number of potential predictors we initially considered. Yet, it is still not fully understood whether and when complex ensemble machine learning techniques offer real value over traditional methods in clinical prediction tasks (18). We agree with previous findings on this question that a strong non-linear relationship between the predictors and the response appears to be an important prerequisite (19) and that the signal-to-noise ratio ought to be high (20).

313: If your intention was to find complex interaction, why do you just present results from the logistic regression without any interaction?

We agree that the wording was misleading. We wanted to take advantage of complex interactions if there were any. We changed the sentence accordingly:

This allowed us to apply powerful machine learning methods for fracture prediction, which have the potential to take advantage of complex interactions and unknown non-linear effects.

However, the fact that we found no difference between techniques that can capture interactions and those that only account for main effects indicates that there are no relevant and robust interactions to report. Nonetheless, we added evaluation criteria for the models with interactions. These show no improvement over the simpler models. Therefore, we report the simplest model.

319: I don't see any memory problems arising from a data frame with 20000 individuals and probably less than 100 features.

The sentence may have been unclear. We would have had memory issues if we had worked with the original training data, which contained n=230.468 individuals. The corresponding paragraph was changed to make that more clear.

359: software

Thank you. We corrected this mistake.

Comments of Reviewer 2:

a\) The sentence started from the line 80 " Moreover, claims data in Germany ......within the observational period" was not clear, please clarify

Thank you for pointing this out. We elaborated on the statement:

Moreover, claims data in Germany include information, which can be difficult to obtain when questionnaires or interviews are used, because -- as opposed to questionnaires and interviews -- the data is not prone to recall (e.g. patients who do not remember their prescription dates) or recruitment biases (i.e. the full cohort of insuree's and not just those who choose to participate are assessed).

b\) In the paragraph of "sample", the baseline for the study was not well defined. For an example, in line 108, the baseline is April, 1 2010 and pre baseline is 24 months. Were patients allowed to enter the cohort after April, 1, 2010?

We rephrased the paragraph to make it more clear that patients who switched to the social insurance during the pre-period or after April, 1, 2010 were excluded:

Notably, the dataset is limited to people working in agriculture and their families, because the data provider is the German agricultural sickness fund -- in german: Sozialversichung für Landwirtschaft, Forsten und Gartenbau (SVLFG). We only included individuals, who were insured by the SVLFG on April 1, 2010 (baseline) with continuous insurance coverage for the 24 months pre-period -- i.e. we excluded patients who switched to the SVLFG during the pre-period or after April, 1, 2010.

c\) In the paragraph of " Outcome variable", "hip fracture occurring within 4 years of baseline" was the outcomes of interest? Please clarify baseline and prebaseline.

In the revised manuscript, we mention the exact time period:

The outcome variable was the first hip fracture occurring within 4 years after the index date -- i.e. between April 1 2010 and 31 March 2014.

d\) It was not clear whether the patients were allowed to have multiple fractures or only the first one. We assessed the delay between the index date and the first fracture that occurred. Thus, we did not differentiate between a patient that received multiple fracture in the observational period or one fracture. As a predictor, we included the information, whether a patient had at least 1 fracture in the pre-period. Consequently, it was allowed to have multiple fractures within the preperiod, but it was not explicitly accounted for in our model.

We changed two relevant sentences to make this more clear:

We further assessed whether at least one prior fracture within 2 years preceding baseline was recorded (yes/no).

The outcome variable was the first hip fracture within 4 years.

e\) Please explain why some variables were evaluated using 2 years pre baseline, but some factors were evaluated in the seven month before baseline.

We differentiated between predictors related to the individual fracture history and predictors related to current medications used.

Regarding the fracture history, an association between prior fractures and fracture risk is well established, but in previous validation studies -- e.g. during the validation of QFracture (21) -- it was not explicitly assessed whether the predictive validity of prior fractures depends on the recency of the prior fracture. Thus, we used the entire available preperiod to detect previous fractures.

Regarding risk factors related to medication use, it was found that the recency of the prescribed medication matters when predicting fracture risk. For instance, for oral corticosteroids, it was observed that fracture risk increases rapidly after the commencement of oral corticosteroid therapy, but reverses sharply toward baseline levels after discontinuation of oral corticosteroids (22). Consequently, a two year preperiod for assessing medication use would be too long, because insurees may have already stopped taking these medications.

f\) This paper used prescribed medications as a surrogate for diseases associated with fracture risk, however, many medications have multiple indications. Has these surrogates been validated yet?

Thank you for pointing that out. Maybe it was unclear in our previous draft that not all of the assessed prescriptions were surrogates for diseases. We agree that some of the medications we included have multiple indications. However, we also wanted to include medications that have multiple indications but were consistently associated with fracture risk in previous studies such as psychotropic drugs (23). In the revised version of the manuscript we differentiate between reliable surrogate variables (e.g. antiparkinson agents) and simple medication based risk factors.

We recognise that the ascertainment of (co-)morbidities proves a challenge in (administrative) ambulatory claims data. The lack of reliability of diagnosis coding in the ambulatory setting has been repeatedly shown (24, 25). Therefore, we solely considered drug exposure as surrogate variable, but no ambulatory ICD-10 diagnoses to identify and define conditions that have been associated with increased fracture risk such as Parkinson\'s disease (26). Prescribed medications whose ATC Classification starts with N04 are almost exclusively used to manage Parkinson\'s disease and are therefore a reliable indication for that particular disorder. This prescription based measure was chosen, because using the most reliable source of information (i.e. hospital diagnoses) would have introduced considerable bias, because in this case only individuals with a hospital stay would have been recorded. In addition, we included medications that have multiple indications but were consistently associated with fracture risk in previous studies such as psychotropic drugs (23).

g\) Suggest to also use logistic regression backward as it is has been reported more conservative

Thank you for this suggestions. We reported the results on the logistic regression with backward selection as well. Moreover, we revised the superlearner model. In the revised version of the manuscript, the superlearner considers both the logistic regression with backward and forward selection as candidate algortihms.

We also followed the suggestions made by Reviewer 1 to include an alternative specification of the regression models with interactions (with age or gender). Our revised superlearner model chose the logistic regression with interactions and backward selection as the most suitable candidate among the four alternative specifications.

h\) The analysis section is clear and well written

Thank you.

i\) Suggest the authors to add the time period for the medications in table 1

We added the time period to table 1.

j\) Please also provide the characteristics for patients risk during the follow up time.

We are uncertain whether we understand this comment correctly. It is unconventional to provide sample characteristics for the follow up period as well. Usually, the baseline characteristics are provided to describe the sample for which outcomes are assessed. However, we added the number of patients that switched to a different statutory health insurance and those that were lost to follow-up due to death, because these characteristics might influence the performance of the prediction model.
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